Pirfenidone ameliorates hypertrophic scar through inhibiting proliferation and migration of fibroblasts by regulating the Wnt/GSK-3β/β-catenin signaling pathway.
ZhengHao Dai, YiWen Jiang, Hang Guo, YuTing Lu, WeiGuo Chen, Tao Liang
{"title":"Pirfenidone ameliorates hypertrophic scar through inhibiting proliferation and migration of fibroblasts by regulating the Wnt/GSK-3β/β-catenin signaling pathway.","authors":"ZhengHao Dai, YiWen Jiang, Hang Guo, YuTing Lu, WeiGuo Chen, Tao Liang","doi":"10.1093/jbcr/iraf040","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic scar (HS) is a prevalent complication that arises from burn injuries. While Pirfenidone (PFD) is known to be an effective antifibrotic agent, its precise effects on HS caused by burn injuries are still unclear. This study was to assess the influence of PFD on HS fibroblasts and investigate the underlying mechanism. HS tissue and normal skin tissue samples were collected, and fibroblasts were isolated from HS tissues and normal skin. The cytotoxic effect was detected by lactate dehydrogenase (LDH). Cell proliferation was detected by CCK-8 and EdU methods, and migration was detected by Transwell. Transforming growth factor β1 (TGF-β1), α-smooth muscle actin (α-SMA), and type I collagen (COL-I) mRNA expression levels were analyzed by RT-qPCR. TGF-β1, α-SMA, COL-I, and APC protein expression levels, as well as phosphorylation of GSK-3β and β-catenin were detected by Western blot. The results indicated that PFD inhibited the proliferation of HS fibroblasts without cytotoxicity. PFD inhibited the migration of HS fibroblasts and differentiation by inhibiting TGF-β1, α-SMA, and Col-I expression. PFD reduced the phosphorylation of GSK-3β and β-catenin, suppressed APC protein expression, and blocked the Wnt/GSK-3β/β-catenin cascade. PFD can ameliorate HS after burn injuries and inhibit proliferation and differentiation of HS fibroblasts through the Wnt/GSK-3β/β-catenin cascade.</p>","PeriodicalId":15205,"journal":{"name":"Journal of Burn Care & Research","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Burn Care & Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jbcr/iraf040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertrophic scar (HS) is a prevalent complication that arises from burn injuries. While Pirfenidone (PFD) is known to be an effective antifibrotic agent, its precise effects on HS caused by burn injuries are still unclear. This study was to assess the influence of PFD on HS fibroblasts and investigate the underlying mechanism. HS tissue and normal skin tissue samples were collected, and fibroblasts were isolated from HS tissues and normal skin. The cytotoxic effect was detected by lactate dehydrogenase (LDH). Cell proliferation was detected by CCK-8 and EdU methods, and migration was detected by Transwell. Transforming growth factor β1 (TGF-β1), α-smooth muscle actin (α-SMA), and type I collagen (COL-I) mRNA expression levels were analyzed by RT-qPCR. TGF-β1, α-SMA, COL-I, and APC protein expression levels, as well as phosphorylation of GSK-3β and β-catenin were detected by Western blot. The results indicated that PFD inhibited the proliferation of HS fibroblasts without cytotoxicity. PFD inhibited the migration of HS fibroblasts and differentiation by inhibiting TGF-β1, α-SMA, and Col-I expression. PFD reduced the phosphorylation of GSK-3β and β-catenin, suppressed APC protein expression, and blocked the Wnt/GSK-3β/β-catenin cascade. PFD can ameliorate HS after burn injuries and inhibit proliferation and differentiation of HS fibroblasts through the Wnt/GSK-3β/β-catenin cascade.
期刊介绍:
Journal of Burn Care & Research provides the latest information on advances in burn prevention, research, education, delivery of acute care, and research to all members of the burn care team. As the official publication of the American Burn Association, this is the only U.S. journal devoted exclusively to the treatment and research of patients with burns. Original, peer-reviewed articles present the latest information on surgical procedures, acute care, reconstruction, burn prevention, and research and education. Other topics include physical therapy/occupational therapy, nutrition, current events in the evolving healthcare debate, and reports on the newest computer software for diagnostics and treatment. The Journal serves all burn care specialists, from physicians, nurses, and physical and occupational therapists to psychologists, counselors, and researchers.